Recent advances in the discovery of tissue factor/factor VIIa inhibitors and dual inhibitors of factor VIIa/factor Xa

Current Pharmaceutical Design

Volumn 11, Issue 32, 2005, Pages 4207-4227

  Kranjc, A ^a   Kikelj, D ^a   Peterlin Masic, Lucija ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Anticoagulants; Dual inhibitors; Factor VIIa; Tissue factor; Tissue factor factor VIIa inhibitors

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 4H 3,1 BENZOXAZIN 4 ONE DERIVATIVE; ANTICOAGULANT AGENT; ANTICOAGULANT PROTEIN; ARGATROBAN; AROMATIC AMIDE; BENZOQUINONE DERIVATIVE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A INHIBITOR; COUMARIN; DESULFATOHIRUDIN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NAPSAGATRAN; PHENYLGLYCINE; PROTEIN INHIBITOR; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RO 67 8698; SULFONAMIDE; TETRAPEPTIDE; THROMBIN; THROMBIN INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG; XIMELAGATRAN;

BLEEDING; BLOOD CLOTTING; BLOOD VESSEL INJURY; COMPLEX FORMATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

ANTICOAGULANTS; ANTITHROMBIN III; DRUG DESIGN; FACTOR VIIA; HUMANS; THROMBOPLASTIN;

EID: 27944461772     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774913282     Document Type: Review

References (89)

1. Gresele P, Agnelli G. Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci 2002; 23: 25-32.
2. Vacca JP. New advances in the discovery of thrombin and factor Xa inhibitors. Curr Opin Chem Biol 2000; 4: 394-400.
3. Rewinkel JBM, Adang AEP. Strategies and Progress Towards the Ideal Orally Active Thrombin Inhibitor. Curr Pharm Design 1999; 5: 1043-72.
4. Hirsh J. Current anticoagulant therapies - unmet clinical needs. Thromb Res 2003; 109: S1-S8.
5. Veldman A, Hoffman M, Ehrenforth S. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. Curr Med Chem 2003; 10: 797-811.
6. Sajadi S, Ezekowitz MD, Dhond A, Netrebko P. Tissue factor pathway inhibitors as a novel approach to antithrombotic therapy. Drug News Perspect 2003; 16: 363-9.
7. Golino P. The inhibitors of the tissue factor:factor VII pathway. Thromb Res 2002; 106, V257-65.
8. Kirchofer D, Nemerson Y. Initiation of blood coagulation: the tissue factor/factor VIIa complex. Curr Opin Biotechnol 1996; 7: 386-91.
9. Girard TJ, Nicholson NS. The role of tissue factor/factor VIIa in the pathophysiology of acute thrombotic formation. Curr Opin Pharmacol 2001; 1: 159-63.
10. Vlasuk GP, Rote WE. Inhibition of Factor VIIa/Tissue Factor with Nematode Anticoagulant Protein c2. Trends Cardiovasc Med 2002; 12: 325-31.
11. Robinson LA, Saiah EMK. Anticoagulants: Inhibitors of the factor VIIa tissue factor pathway. Annu Rep Med Chem 2002; 37: 85-94.
12. Moons AHM, Levi M, Peters RJG. Tissue factor and coronary artery disease. Cardiovasc Res 2002; 53: 313-25.
13. Colman RW. In: Hemostasis and thrombosis: basic principles and clinical prectice. 4th ed. Philadelphia, Lippincott Williams and Wilkins. 2001; 89-101.
14. Khrenov AV, Ananyeva NM, Griffin JH, Saenko EL. Coagulation Pathways in Atherothrombosis. Trends Cardiovasc Med 2002; 12: 317-24.
15. Carmeliet P, Collen D. Molecules in focus - Tissue factor. Int J Biochem Cell Biol 1998; 30: 661-7.
16. Dahlbäck B. Blood coagulation. Lancet 2000; 355: 1627-32.
17. Davie EW. Biochemical and Molecular Aspects of the Coagulation Cascade. Thromb Haemost 1995; 74: 1-6.
18. Bauer KA. Selective Inhibition of Coagulation Factors: Advances in Antithrombotic Therapy. Semin Thromb Hemost 2002; 28: 15-24.
19. Bates SM, Weitz JI. Emerging anticoagulant drugs. Arterioscler Thromb Vasc Biol 2003; 23: 1491-500.
20. Olsson SB and Executive Steering Committee on behalf of the SPORTIF III Investigators. Lancet 2003; 362: 1691-8.
21. Hirsh J. New anticoagulants. Am Heart J 2001; 142, S3-8.
22. Suleymanov OD, Szalony JA, Salyers AK, Lachance RM, Parlow JJ, South MS, et al. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: Comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. J Pharmacol Exp Ther 2003; 306: 1115-21.
23. Banner DW, DArcy A, Chene C, Winkler FK, Guha A, Konigsberg WH, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380: 41-6.
24. Kemball-Cook G, Johnson DJD, Tuddenham EGD, Harlos KJ. Crystal Structure of Active Site-Inhibited Human Coagulation Factor VIIa (des-Gla). J Struct Biol 1999; 127: 213-23.
25. Eigenbrot C, Kirchhofer D. New insight into how tissue factor allosterically regulates Factor VIIa. Trends Cardiovasc Med 2002; 12: 19-26.
26. Persson E. Structure of human coagulation activated factor VII. Blood Coagul Fibrinolysis 2000; 11: S15-17.
27. Pike ACW, Brzozowski AM, Roberts SM, Olsen OH, Persson E. Structure of human factor VIIa and its implications for the triggering of blood coagulation. Proc Natl Acad Sci USA 1999; 96: 8925-30.
28. Sichler K, Banner DW, D'Arcy A, Hopfner KP, Huber R, Bode W, Kresse GB, Kopetzki E, Brandstetter H. Crystal structures of uninhibited factor VIIa link its cofactor and substrate-assisted activation to specific interactions. J Mol Biol 2002; 322: 591-603.
29. Banner D W. The Factor VIIa/Tissue Factor Complex. Thromb Haemost 1997; 78 (1), 512-515.
30. Kranjc A, Kikelj D. Dual inhibitors of the blood cogulation enzymes. Curr Med Chem 2004; 11: 2535-2547.
31. Kirchofer D, Banner DW. Molecular and Structural Advances in Tissue Factor-Dependent Coagulation. Trends Cardiovasc Med 1997; 7: 316-24.
32. Young WB, Kolesnikov A, Rai R, Sprengeler PA, Leahy EM, Shrader WD, et al. Bioorg Med Chem Lett 2001; 11: 2253-6.
33. South MS, Case BL, Wood RS, Jones DE, Hayes MJ, Girard TJ, et al. Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex. Bioorg Med Chem Lett 2003; 13: 2319-25.
34. Parlow JJ, Case BL, Dice TA, Fenton RL, Hayes MJ, Jones DE, et al. Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex. J Med Chem 2003; 46: 4050-62.
35. Parlow JJ, Stevens AM, Stegeman RA, Stallings WC, Kurumbail RG, South MS Synthesis and crystal structures of substituted benzenes and benzoquinones as tissue factor VIIa inhibitors. J Med Chem 2003; 46: 4297-312.
36. South MS, Dice TA, Girard TJ, Lachance RM, Stevens AM, Stegeman RA, et al. Polymer-Assisted solution-Phase (PASP) parallel synthesis of an α-Ketothiazole library as tissue factor VIIa inhibitors. Bioorg Med Chem Lett 2003; 13: 2363-7.
37. Safar P, Safarava A, Wildgoose P. Factor VIIa inhibitors. 2000; WO 00/15658.
38. Defossa E, Heinelt U, Matter H, Safar P, Klinger O, Schudok M, Zoller G. Factor VIIa inhibitors. 2000; WO 00/75172.
39. Shiraishi T, Kadono S, Haramura M, Sato H, Kozono T, Koga T, et al. Peptide derivatives. 2002; WO 02/62829.
40. Jakobsen P, Pedersen BR, Persson E. Inhibitors of the tissue factor/factor VIIa-induced coagulation: synthesis and in vitro evaluation of novel specific 2-aryl substituted 4H-3, 1-benzoxazin-4-ones. Bioorg Med Chem 2000; 8: 2095-103.
41. Jakobsen P, Horneman AM, Persson E. Inhibitors of the tissue factor/factor VIIa-induced coagulation: synthesis and in vitro evaluation of novel 2-aryl substituted pyrido[3, 4-d][1, 3]-, pyrido[2, 3-d][1, 3]-, pyrazino[2, 3-d][1, 3]-, pyrimido[4, 5-d][1, 3]-, pyrazolo[3, 4-d][1, 3]-, thieno[3, 2-d][1, 3]- and thieno[2, 3-d][1, 3]-oxazin-4-ones. Bioorg Med Chem 2000; 8: 2803-12.
42. Senokuchi K, Ogawa K. Amidino derivatives and drugs containing the same as the active ingredient. 1999; WO 99/41231.
43. Kohrt JT, Filipski KJ, Rapundalo ST, Cody WL, Edmunds JJ. An efficient synthesis of2-(3-(4-amidinophenylcarbamoyl)naphthalene-2-yl)-5-((2, 2methylpropyl) carbamoyl)benzoic acid: a factor VIIa inhibitor discovered by the ONO Pharmaceutical company. Tetraherdon Lett 2000; 41: 6041-44.
44. Goldsmith R, Zhou A, Zhu Y, Artis DR, Dina MS, Flygare JA, et al. Serine protease inhibitors. 2000; WO 00/41531.
45. Wessel HP, Kuehne H, Obst U, Ackermann J, Alig L, Groebke K, et al. Phenylglycine derivatives. 2000; WO 00/35858.
46. Wessel HP, Kuehne H, Obst U, Alig L, Hilpert K, Groebke K. Phenylglycine derivatives. 2001; WO 01/90051.
47. Obst U, Alig L, Groebke Zbinder K. Water soluble phenylglycine derivatives. 2003; WO 03/066588.
48. Bounameaux H, Ehringer H, Gast A, Hulting J, Rasche H, Rapold HJ. Thromb Haemost 1999; 81: 498.
49. Sanderson PEJ, Lyle TA, Cutrona KJ, Dyer DL, Dorsey BD, McDonough CM, et al. Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates. J Med Chem 1998; 41: 4466-74.
50. Suleymanov OD, Szalony JA, Salyers AK, Lachance RM, Parlow JJ, South MS, et al. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: Comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. J Pharmacol Exp Ther 2003; 306: 1115-21.
51. Pinto DJP, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, et al. Discovery of 1-(3-(aminomethyl)phenyl)-N-[3-fluoro-2-methylsulfonyl)-(1, 1′-biphenyl)-4-yl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2001; 44: 566-78.
52. Sanderson PE, Lyle TA, Cutrona KJ, Dyer DL, Dorsey BD, McDonough CM, et al. Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridionone or 3-aminopyrazinone acetamide peptidomimetic template. J Med Chem 1998; 41: 4466-74.
53. Parlow JJ, Kurumbail RG, Stegeman RA, Stevens AM, Stallings WC, South MS. Design, synthesis, and crystal structure of selective 2-pyridone tissue factor VIIa inhibitors. J Med Chem 2003; 46: 4696-701.
54. Parlow JJ, South MS. Synthesis of 2-pyridones as tissue factor VIIa inhibitors. Tetrahedron 2003; 59: 7695-701.
55. Parlow JJ, Kurumbail RG, Stegeman RA, Stevens AM, Stallings WC, South MS. Synthesis and X-ray crystal structures of substituted fluorobenzene and benzoquinone inhibitors of the tissue factor VIIa complex. Bioorg Med Chem Lett 2003; 13: 3721-25.
56. Neumann WL, Case B, Huang W, Jones DE, Parlow JJ, Reitz DB, et al. Substituted polycyclic and heteroaryl pyridines useful for selective inhibition of the coagulation cascade. 2002; WO 02/42272.
57. South MS, Webber RK, Huang H-C, Toth MV, Moormann AE, Snyder JS, et al. Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade. 2003; WO 03/28729.
58. Slusasrchyk WA, Bolton SA, Herpin T, Bisacchi GS, Pi Z, Priestley E. Ureido-substituted aniline compounds useful as serine protease inhibitors. 2004; WO 04/000788.
59. Satoh, T, Okamoto Y, Asano O, Watanabe N, Nagakura T, Saeki T, et al. Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them. EP patent: EP 1312602.
60. Gubernator N, Bai X, Gu X, Robinson L, Saiah E, Zhou J. Tetrahydroquinoline derivatives as antithrombotic agents. 2003; WO 03/015715.
61. Zhang X. Amino-bicyclic pyrazinones and pyridinones as coagulation serine protease inhibitors. 2004; WO 04/002405.
62. Glunz PW. Bicyclic pyrimidinones as coagulation cascade inhibitors. 2004; WO 04/002406.
63. Sagi K, Fujita K, Sakurai K, Sugiki M, Takehana S, Tashiro K, et al. Amidinophenylpyruvic acid derivative. 2001; WO 01/42199.
64. Leahy EM. Factor VIIa inhibitors. 2002; WO 02/14307.
65. Rai R, Young WB, Kolesnikov A, Shrader WD. 2-[5-(5-Carbami-midoyl-1H-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor VIIa inhibitors. 2003; WO 03/068756.
66. Roussel P, Bradley M, Kane P, Bailey C, Arnold R, Cross A. Inhibition of the Tissue factor/factor VIIa complex - lead optimisation using combinatorial chemistry. Tetrahedron 1999; 55: 6219-30.
67. Klinger O, Matter H, Schudok M, Bajaj SP, Czech J, Lorenz M, et al. Design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors. Bioorg Med Chem Lett 2003; 13: 1463-67.
68. Klingler O, Schudok M, Nestler HP, Matter H, Schreuder H. Factor VIIa inhibitory (thio) urea derivatives, their preparation and their use. EP Patent: EP 1162194.
69. Matter H, Klingler O, Schudok M, Nestler HP, Schreuder H. Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation and their use. 2002; WO 02/28823.
70. Matter H, Szillat H, Klingler O, Schudok M, Nestler HP, Schreuder H. Urea derivatives with antiproteolytic activity. 2003; WO 03/002524.
71. Juraszyk H, Dorsch D, Mederski W, Tsaklakidis C, Barnes C, Gleitz J. Cyclic amino acid derivatives. 2002; WO 02/06269.
72. Mederski W, Juraszyk H, Dorsch D, Tsaklakidis C, Gleitz J, Barnes C. Acetamide derivatives and the use thereof as inhibitors of coagulation factors Xa and VIIa. 2002; WO 02/10127.
73. Mederski W, Juraszyk H, Dorsch D, Tsaklakidis C, Gleitz J, Barnes C, et al. Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumors. 2002; WO 02/070471.
74. Mederski W, Cezanne B, Tsaklakidis C, Dorsch D, Barnes C, Gleitz J. Semicarbazide derivatives and their use as antithrombotics. 2003; WO 03/074479.
75. Song Y, Clizbe L, Bhakta C, Teng W, Wong P, Huang B, et al. Design and Synthesis of Factor Xa Inhibitors and Their Prodrugs. Bioorg Med Chem Lett 2003; 13: 297-300.
76. Zhang P, Zuckett JF, Woolfrey J, Tran K, Huang B, Wong P, et al. Design, Synthesis, and SAR of Monobenzamidines and Aminoisoquinolines as Factor Xa Inhibitors. Bioorg Med Chem Lett 2002; 12: 1657-61.
77. 1 structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides. Bioorg Med Chem Lett 2002; 12, 1651-5.
78. Song Y, Clizbe L, Bhakta C, Teng W, Li W, Wong P, et al. Substituted Acrylamides as Factor Xa Inhibitors: Improved Bioavailability by P1 Modification. Bioorg Med Chem Lett 2002; 12: 2043-6.
79. Dorsch D, Mederski W, Tsaklakidis C, Cezanne B, Gleitz J, Barnes C. Phenyl derivatives. 2002; WO 02/057236.
80. Mederski W, Tsaklakidis C, Cezanne B, Dorsch D, Barnes C, Gleitz J. Semicarbazide derivatives for combating thromboembolic diseases. 2003; WO 03/093254.
81. Raddatz P, Dorsch D, Gleitz J, Barnes C, Koert U, Volger M. Carbohydrate derivatives. 2003; WO 03/002568.
82. Cezanne B, Dorsch D, Mederski W, Tsaklakidis C, Barnes C, Gleitz J. N-'4-(2-imino-pyrrolidin-1-yl)phenyl!-acetamide and corresponding piperidine derivatives as factor Xa inhibitors for the treatment of thrombo-embolic diseases. 2003; WO 03/084533.
83. Dorsch D, Cezanne B, Tsaklakidis C, Mederski W, Gleitz J, Barnes C. Phenyl derivatives as factor Xa inhibitors. 2003; WO 03/013531.
84. Dorsch D, Cezanne B, Tsaklakidis C, Mederski W, Gleitz J, Barnes C. Derivatives of phenoxy-N-′4-(isothiazolidin-1, 1-dioxid-2-yl)pheny!-valerian-acid amide and other compounds as inhibitors of the coagulation factor Xa in the treatment of thrombboembolic disease and tumors. 2003; WO 03/039543.
85. Dorsch D, Mederski W, Tsaklakidis C, Cezanne B, Gleitz J, Barnes C. 2002; WO 02/48099.
86. Sanderson PEJ, Cutrona KJ, Dyer DL, Krueger JA, Kuo LC, Lewis SD, et al. Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'Distal binding pocket'. Bioorg Med Chem Lett 2003; 13, 161-4.
87. Casu B, Guerrini M, Torri G. Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate. Curr Pharm Design 2004; 10(9): 939-49.
88. Gould WR, Leadley RJ. Recent advances in the discovery and development of direct coagulation factor Xa inhibitors. Curr Pharm Design 2003; 9(28): 2337-47.
89. Mourao PA. Use of sulfated facans as anticoagulant and antithrombotic agents: future perspectives. Curr Pharm Design 2004; 10(9): 967-81.